



## **Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017**

**HOUSTON—November 3, 2017** – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 10, 2017 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2017 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time, and refer to conference ID 3166609. A live audio webcast of the call will also be available on the Presentations section of the Company's website, [www.biopathholdings.com](http://www.biopathholdings.com). An archived webcast will be available on the Bio-Path website approximately two hours after the event.

### **About Bio-Path Holdings, Inc.**

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at <http://www.biopathholdings.com>.

###

**Contact Information:**

**Investors**

Will O'Connor  
Stern Investor Relations  
212-362-1200  
[will@sternir.com](mailto:will@sternir.com)

Doug Morris  
Investor Relations  
Bio-Path Holdings, Inc.  
832-742-1369